Deep Brain Stimulation Device Market Report 2025

The deep brain stimulation device market size has grown rapidly in recent years. It will grow from $1.54 billion in 2024 to $1.72 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increased prevalence of neurological disorders, aging population, limited efficacy of medications, increased awareness and acceptance, improved surgical techniques.

The deep brain stimulation device market size is expected to see rapid growth in the next few years. It will grow to $2.67 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to expanding indications for dbs, rising healthcare expenditure, development of next-generation devices, increasing patient acceptance, government initiatives and funding, collaborations and partnerships. Major trends in the forecast period include patient-centric design and user interface, research and development in closed-loop neuromodulation, telehealth integration, regulatory pathway clarifications, increased collaboration and partnerships.

The anticipated growth in the deep brain stimulation (DBS) device market is expected to be propelled by the increasing prevalence of neurological diseases. Neurological disorders, affecting the central and peripheral nervous systems, can be effectively addressed by DBS devices, which are designed to regulate abnormal brain activity and rectify chemical imbalances contributing to various conditions. For instance, as of February 2023, the World Health Organization reported that approximately 50 million people globally were living with epilepsy. Moreover, a 2022 report from the Parkinson’s Foundation noted a significant increase in new Parkinson's disease diagnoses, reaching 90,000 per year, marking a 50% surge from the previously expected rate of 60,000 diagnoses per year. This surge in neurological disorders is a significant driver behind the growth of the deep brain stimulation device market.

The increasing incidence of chronic diseases, particularly epilepsy, is set to further fuel the growth of the deep brain stimulation devices market. Epilepsy, characterized by recurrent and unprovoked seizures, is witnessing a global rise in cases, intensifying the demand for advanced interventions. Deep brain stimulation devices offer a targeted and effective approach to managing seizures by modulating abnormal brain activity. This provides a valuable alternative for individuals seeking improved seizure control and an enhanced quality of life. As of May 2022, the Centers for Disease Control and Prevention (CDC) reported that approximately 3 million adults in the United States are living with epilepsy. The rising incidence of chronic diseases, including epilepsy, is a key factor driving the growth of the deep brain stimulation devices market.

Leading companies in the deep brain stimulation device market are focusing on technological advancements, including connected care technology, to improve patient care by enabling remote programming, enhancing communication between patients and healthcare providers, and optimizing treatment outcomes for individuals with movement disorders. Connected care technology involves the integration of digital tools and platforms that promote continuous communication and data exchange between patients and healthcare providers, thereby enhancing patient monitoring, treatment management, and overall healthcare delivery. For example, in January 2024, Abbott Laboratories, a U.S.-based healthcare and medical device company, received approval from the U.S. Food and Drug Administration for the Liberta RC DBS system, which is the smallest rechargeable deep brain stimulation device designed for treating movement disorders. Key features of the Liberta RC DBS system include remote programming capabilities via the NeuroSphere Virtual Clinic, a requirement of only 10 recharges per year, and a compact design that is 31% smaller than competing devices. Additionally, it features a wireless charging system that can recharge the device every 37 days and offers customizable controls through an Abbott patient controller or compatible iOS devices.

Major players in the deep brain stimulation devices market are forging strategic partnerships and collaborations to fortify their market positions and drive innovation. Such partnerships, characterized by collaborative efforts between multiple organizations, aim to achieve specific business objectives or goals. A case in point is the collaboration announced in August 2022 between Aster Medcity, a multi-specialty hospital based in India, and Medtronic, a leading provider of medical technology, services, and solutions in India. This strategic alliance seeks to establish a comprehensive and advanced Deep Brain Stimulation (DBS) program for Parkinson's patients in India, thereby enhancing patients' access to advanced DBS therapy through the Parkinson's and Movement Disorder Centre at Aster Medcity.

In August 2022, Medtronic, a prominent Ireland-based medical device company specializing in the manufacturing of deep brain stimulation devices, initiated a collaborative effort with Aster MedCity, a multi-specialty hospital based in India. This strategic partnership is focused on leveraging Medtronic's Deep Brain Stimulation (DBS) technology to enhance the treatment protocols for patients diagnosed with Parkinson’s disease. The collaboration underscores the commitment of both organizations to advancing patient care through the application of innovative medical technologies, particularly in the realm of deep brain stimulation for Parkinson's disease management.

Major companies operating in the deep brain stimulation device market include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Functional Neuromodulation Ltd, NeuroPace, Inc., LivaNova PLC, Beijing PINS Medical Co. Ltd., SceneRay Corporation, Synapse Biomedical Inc., Deep Brain Innovation LLC, Nevro Corp., MicroPort NeuroTech, Stimwave LLC, Sapiens Neuro, Neuronetics Inc., BlueWind Medical Ltd., Brainsway Ltd., Neuralink Corporation, Med-Ally LLC, Axion BioSystems Inc., CereGate GmbH, NeuroSigma Inc., Bioinduction Ltd., Alpha Omega Engineering Ltd., Helius Medical Technologies, ANM Adaptive Neuromodulation GmbH, MagVenture A/S, Precisis AG, Monteris Medical Inc.

North America was the largest region in the deep brain stimulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global deep brain stimulation devices market report during the forecast period. The regions covered in the deep brain stimulation device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep brain stimulation device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Deep brain stimulation (DBS) devices are specialized medical instruments designed to administer electrical currents directly to specific areas of the brain. These electrical impulses serve to address chemical imbalances within the brain that may contribute to various neuropsychological disorders. DBS is a therapeutic approach employed for the treatment of these conditions.

The primary product types within the category of deep brain stimulation devices are single-channel deep brain stimulators and dual-channel deep brain stimulators. A single-channel deep brain stimulator is a medical device specifically engineered to deliver electrical currents directly to targeted areas of the brain. These devices find application in addressing a range of conditions, including epilepsy, essential tremor, obsessive-compulsive disorder (OCD), depression, dystonia, Parkinson’s disease, and pain management. These devices are utilized in various healthcare settings such as hospitals, neurology clinics, ambulatory surgical centers, and research centers.

The deep brain stimulation devices market research report is one of a series of new reports that provides deep brain stimulation devices market statistics, including deep brain stimulation devices industry global market size, regional shares, competitors with a deep brain stimulation devices market share, detailed deep brain stimulation devices market segments, market trends, and opportunities, and any further data you may need to thrive in the deep brain stimulation devices industry. This deep brain stimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The deep brain stimulation devices market consists of sales of neurostimulators, leads, extensions, and handheld controllers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.